Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Mesopancreas Excision in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma (MESO-PDAC)

13 novembre 2026 aggiornato da: Saleh Khairy Saleh MD, Minia University

Mesopancreas Excision Versus Standard Dissection During Pancreaticoduodenectomy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Randomized Controlled Trial

Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is treated when it arises in the head of the pancreas and can be removed by an operation called pancreaticoduodenectomy (the Whipple operation), followed by chemotherapy. Even after this operation the cancer returns in most patients. One important reason is that microscopic cancer cells are often left at the cut edges of the removed tissue, especially at the edge facing the superior mesenteric artery, the main artery that supplies the intestine. The tissue in this area, behind the head of the pancreas, is called the mesopancreas. It contains fat, lymph vessels, lymph nodes and nerves, through which pancreatic cancer commonly spreads.

Total mesopancreas excision is a refinement of the standard operation. The surgeon removes the whole mesopancreas in one piece together with the head of the pancreas by dissecting directly along the right side of the superior mesenteric artery, in the same way that the whole fatty envelope of the rectum is removed in rectal cancer surgery. Studies that compared patients operated on with and without this technique suggest that it may leave fewer cancer cells behind and reduce the chance of the cancer returning in the operated area, without increasing complications. Those studies were not randomized, however, so it is still unknown whether the technique itself is responsible for these benefits.

In this single-center randomized controlled trial, 110 adults with removable (resectable) cancer of the head of the pancreas will be assigned by chance, during the operation and after the surgeon has confirmed that the tumor can be removed, to pancreaticoduodenectomy with total mesopancreas excision or to standard pancreaticoduodenectomy. Patients, and the doctors who examine the removed tissue and the follow-up scans, will not be told which operation was performed. The main question is whether total mesopancreas excision increases the proportion of patients in whom no cancer cells are found within 1 mm of any cut edge (an R0 resection). The trial will also compare complications, diarrhea, recovery, the number of lymph nodes removed, the chance and pattern of cancer recurrence, survival and quality of life over 2 years of follow-up.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

BACKGROUND AND RATIONALE

Pancreaticoduodenectomy followed by adjuvant chemotherapy is the standard treatment for resectable pancreatic ductal adenocarcinoma (PDAC) of the pancreatic head, but most patients develop recurrence, often within 2 years (Groot et al., 2018). Microscopic involvement of the resection margins is a major cause of locoregional failure. When pancreaticoduodenectomy specimens are examined with a standardized protocol of multicolor inking and axial slicing and the 1-mm rule is applied, most PDAC resections are classified as R1 (Verbeke et al., 2006; Esposito et al., 2008; Campbell et al., 2009), and the mesopancreatic margin facing the superior mesenteric artery (SMA) is the most frequently involved site (Gaedcke et al., 2010).

The mesopancreas, introduced as a surgical concept by Gockel et al. (2007), is the retropancreatic compartment of adipose, lymphatic and neural tissue that extends from the pancreatic head and uncinate process to the SMA and the aorta. Total mesopancreas excision (TMpE), analogous to total mesorectal excision for rectal cancer, removes this compartment en bloc by a periadventitial dissection along the right side of the SMA (Adham and Singhirunnusorn, 2012; Kawabata et al., 2012; Inoue et al., 2015). Comparative series have reported higher R0 rates (Kawabata et al., 2012; Xu et al., 2017; Shyr et al., 2025) and larger lymph node yields with fewer locoregional recurrences (Xu et al., 2017; Quero et al., 2020) after TMpE than after standard pancreaticoduodenectomy. A 2024 meta-analysis of nine non-randomized studies (738 patients) found a higher R0 rate (risk ratio 1.24), fewer local recurrences (risk ratio 0.39) and no increase in overall morbidity or mortality, with a non-significant increase in postoperative diarrhea (da Silva et al., 2024). The 2026 international MESODELPHI consensus agreed on a unified definition and boundaries of the mesopancreas, favored TMpE for curative-intent surgery, and called for further investigation of its effect on survival (Leite et al., 2026). No randomized trial comparing TMpE with standard pancreaticoduodenectomy has been published (Ramia et al., 2018; da Silva et al., 2024).

At the Liver and GIT Hospital, Minia University, a single-arm cohort of 86 patients who underwent pancreaticoduodenectomy with mesopancreas excision for PDAC between 2018 and 2024 had an R0 rate of 84.9% under the Royal College of Pathologists 1-mm rule; recurrence developed in 52 patients (60.5%), with a locoregional component in 31 of them (Saleh et al., 2026). Because that study, like most of the literature, had no control group, the oncological benefit of TMpE over standard pancreaticoduodenectomy remains unproven and requires a randomized comparison.

OBJECTIVES AND HYPOTHESIS

The primary objective is to determine whether pancreaticoduodenectomy with TMpE increases the R0 resection rate, defined as tumor clearance of 1 mm or more at all resection margins, compared with standard pancreaticoduodenectomy in patients with resectable PDAC of the pancreatic head. The hypothesis is that TMpE increases the R0 rate from 60% to 85%.

The secondary objectives are to compare SMA-margin involvement, lymph node yield, locoregional and distant recurrence, disease-free and overall survival, postoperative morbidity (including pancreatic fistula, hemorrhage, delayed gastric emptying, chyle leak and diarrhea), recovery, delivery of adjuvant chemotherapy and quality of life between the two operations.

STUDY DESIGN AND SETTING

This is a single-center, randomized, parallel-group (1:1) superiority trial with masked participants and masked outcome assessors, conducted at the Department of Surgery, Liver and GIT Hospital, Faculty of Medicine, Minia University, Minya, Egypt. The protocol follows the SPIRIT 2025 statement, and the trial will be reported according to CONSORT 2025 and its extension for non-pharmacologic treatments.

SCREENING AND STAGING

Consecutive adults referred with a mass in the pancreatic head or uncinate process are screened. Staging consists of pancreatic-protocol contrast-enhanced multidetector CT of the chest, abdomen and pelvis within 4 weeks before surgery, serum CA19-9, and endoscopic ultrasound with fine-needle aspiration or biopsy when the multidisciplinary tumor board requires a tissue diagnosis. Resectability is defined by NCCN criteria (Tempero et al., 2021). Preoperative biliary drainage is reserved for cholangitis, severe jaundice or an expected delay to surgery, according to unit policy.

RANDOMIZATION AND ALLOCATION CONCEALMENT

A statistician not involved in recruitment or treatment generates the allocation sequence by computer, using permuted blocks of variable size (4 and 6) stratified by venous contact on preoperative CT (no contact versus contact of 180 degrees or less with the superior mesenteric vein or portal vein). Allocations are kept in sequentially numbered, opaque, sealed envelopes outside the operating room. Written informed consent is obtained before surgery. Randomization takes place during the operation, after exploration has excluded peritoneal and liver metastases and confirmed local resectability, when the circulating nurse opens the next envelope of the relevant stratum. Patients found to be unresectable before randomization are not randomized and are recorded as screening failures.

MASKING

The operating surgeons cannot be masked. Participants are not told their allocation until follow-up is complete. Specimens are sent to pathology labeled with the trial number only, with a request form that does not state the allocation, and a second pathologist re-measures the margin distances on the slides. Postoperative complications are graded, and follow-up imaging is reviewed for recurrence, by investigators who did not take part in the operation and are masked to allocation. The statistician analyzes a dataset in which the arms are coded.

INTERVENTIONS

Both arms: All operations are open pancreaticoduodenectomies, pylorus-preserving or pylorus-resecting according to tumor extent, performed by senior hepatopancreatobiliary surgeons of the unit who have used TMpE since 2018 and perform more than 50 pancreaticoduodenectomies per year. Both arms receive the ISGPS standard lymphadenectomy (stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a and 17b; Tol et al., 2014). Portal or superior mesenteric vein resection is performed in either arm when needed for tumor clearance. Reconstruction, drain policy, antibiotic and thromboembolic prophylaxis, and the enhanced-recovery pathway are the same in both arms.

Experimental arm (TMpE): An artery-first approach exposes the SMA at its origin to confirm the absence of arterial involvement. The mesopancreas is excised en bloc with the pancreatic head and uncinate process within these boundaries: the superior mesenteric vein/portal vein axis and the right semicircumference of the SMA anteriorly and medially; the adventitia of the inferior vena cava, left renal vein and aorta posteriorly; the origins of the celiac trunk and SMA superiorly; and the lower border of the uncinate process and the first jejunal vessels inferiorly. The SMA is dissected in the periadventitial plane over its right hemicircumference (about 180 degrees) from the aortic origin to the origin of the first jejunal artery. The inferior pancreaticoduodenal artery, or its common trunk with the first jejunal artery, is ligated at its origin, and the right-sided SMA nerve plexus is removed with the specimen while the left-sided plexus is preserved. Extension of the periarterial clearance up to 270 degrees is allowed only when periarterial tumor extension is suspected during surgery and is recorded as a protocol variation.

Control arm (standard pancreaticoduodenectomy): A conventional vein-first approach is used (Kocher maneuver, tunneling behind the pancreatic neck and transection of the neck). The uncinate process is divided from the superior mesenteric vein and from the right side of the SMA, ligating the pancreaticoduodenal branches close to the pancreas. The SMA is not dissected in the periadventitial plane, its nerve plexus is preserved, and the retropancreatic tissue is not excised as an en bloc compartment; station 14a and 14b nodes are removed superficial to the nerve plexus.

Surgical quality assurance: Standardized photographs of the operative field after resection and of the specimen are taken in every case and reviewed by an independent senior surgeon to confirm that the allocated technique was performed. Crossovers and protocol deviations are documented.

PATHOLOGY PROTOCOL

The surgeon marks the SMA margin and the superior mesenteric vein groove with sutures. Specimens are examined with a standardized protocol based on multicolor inking of the margins and surfaces, axial slicing perpendicular to the duodenal axis at 3 to 5 mm intervals, and extensive sampling (Verbeke et al., 2006). The minimum distance between tumor and each margin is measured microscopically. R0 is defined as clearance of 1 mm or more at all resection margins (SMA, superior mesenteric vein/portal vein groove, posterior, pancreatic neck, bile duct, and proximal and distal enteric margins). R1 is defined as tumor less than 1 mm from any resection margin and is subdivided into direct (0 mm) and indirect (more than 0 mm and less than 1 mm) involvement. Involvement of the anterior pancreatic surface is recorded separately. Lymph nodes are reported by station, staging follows the 8th edition of the AJCC/UICC TNM classification, and perineural, lymphovascular and retropancreatic soft-tissue invasion are recorded.

POSTOPERATIVE CARE, ADJUVANT THERAPY AND FOLLOW-UP

Complications are recorded prospectively for 90 days and graded by the Clavien-Dindo classification (Dindo et al., 2004) and the Comprehensive Complication Index (Slankamenac et al., 2013). Postoperative pancreatic fistula, delayed gastric emptying, post-pancreatectomy hemorrhage and chyle leak follow the ISGPS definitions (Bassi et al., 2017; Wente et al., 2007a; Wente et al., 2007b; Besselink et al., 2017). Diarrhea is graded by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 at every visit for 6 months. Adjuvant chemotherapy is decided by the clinical oncology team, which is masked to allocation: modified FOLFIRINOX for fit patients or gemcitabine plus capecitabine, planned for 6 months and started within 12 weeks of surgery (Neoptolemos et al., 2017; Conroy et al., 2018). Follow-up visits occur at 1, 3, 6, 9, 12, 18 and 24 months, with clinical examination and serum CA19-9 at each visit. Contrast-enhanced CT of the chest, abdomen and pelvis is performed at 3, 6, 9, 12, 18 and 24 months and whenever recurrence is suspected, with MRI, PET-CT or biopsy when needed. Recurrence is classified as locoregional (pancreatic or mesopancreatic bed around the SMA, celiac axis and superior mesenteric vein/portal vein, anastomoses, or regional lymph nodes), distant (liver, lungs, peritoneum, bone, non-regional lymph nodes or other organs) or combined, and is adjudicated by a radiologist masked to allocation. Quality of life is assessed with the EORTC QLQ-C30 at baseline and at 3, 6 and 12 months.

SAMPLE SIZE

The sample size is based on the primary outcome. The expected R0 rate is 60% after standard pancreaticoduodenectomy (Kawabata et al., 2012) and 85% after TMpE, based on the institutional series in which a comparable protocol (axial slicing, margin inking and the 1-mm rule) gave an R0 rate of 84.9% (Saleh et al., 2026). A difference of this size is consistent with the higher R0 rates reported in comparative series and with the mesopancreatic margin being the most common site of R1 resection (Gaedcke et al., 2010; da Silva et al., 2024). Detecting it with 80% power and a two-sided alpha of 0.05 (chi-square test) requires 49 participants per arm. Allowing 10% for post-randomization exclusions (final histology other than PDAC, or withdrawal), 55 participants per arm will be randomized (110 in total). Recruitment is planned over 12 months, from December 2026 to November 2027.

STATISTICAL ANALYSIS

The primary analysis follows a modified intention-to-treat approach: all randomized participants with histologically confirmed PDAC, analyzed in the arm to which they were allocated. A per-protocol analysis excluding crossovers and major protocol deviations is a sensitivity analysis. R0 rates are compared with the chi-square test and reported as the absolute risk difference and risk ratio with 95% confidence intervals; logistic regression adjusted for the stratification factor is a supportive analysis. Other categorical outcomes are compared with the chi-square or Fisher exact test, and continuous outcomes with the t-test or Mann-Whitney U test. Disease-free and overall survival are estimated by the Kaplan-Meier method, compared with the log-rank test and modeled with Cox regression adjusted for the stratification factor. Locoregional and distant recurrence are analyzed as cumulative incidence with death as a competing event (Gray test and Fine-Gray model). Quality-of-life scores are analyzed with linear mixed models. Prespecified subgroup analyses of the primary outcome are by venous contact and by tumor size on CT (2 cm or less versus more than 2 cm). Missing secondary outcome data are handled by multiple imputation if more than 5% are missing. All tests are two-sided at a significance level of 0.05; secondary outcomes are not adjusted for multiplicity and are interpreted as exploratory. Analyses are performed with SPSS version 26 and R.

DATA MANAGEMENT AND MONITORING

Data are recorded on standardized case report forms and entered into a password-protected database with coded identifiers; the primary outcome is verified against source documents for every participant. An independent data and safety monitoring board (a hepatopancreatobiliary surgeon, a clinical oncologist and a biostatistician, none involved in the trial) reviews unmasked safety data, including 90-day mortality, complications of Clavien-Dindo grade IIIa or higher, grade B or C pancreatic fistula and hemorrhage, and diarrhea of CTCAE grade 3 or higher, after 30 and after 55 participants have completed 90 days of follow-up, and may recommend modification or early termination for safety. No interim efficacy analysis is planned. Serious adverse events are reported to the Institutional Review Board according to its requirements.

ETHICS AND DISSEMINATION

The protocol was approved by the Institutional Review Board, Faculty of Medicine, Minia University (MUFMIRB approval number 1702:09/2025, 15 September 2025). The trial is conducted in accordance with the Declaration of Helsinki, ICH Good Clinical Practice and Egyptian Law No. 214 of 2020 on clinical medical research. All participants give written informed consent before surgery, including consent to randomization during the operation, and may withdraw at any time without any effect on their care. Results will be published in a peer-reviewed journal and reported on ClinicalTrials.gov regardless of the findings.

Tipo di studio

Interventistico

Iscrizione (Stimato)

110

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Minya Governorate
      • Minya, Minya Governorate, Egitto
        • Liver and GIT Hospital, Faculty of Medicine, Minia University
        • Contatto:
        • Investigatore principale:
          • Saleh Khairy Saleh, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 18 to 75 years.
  • Solid tumor of the pancreatic head or uncinate process with a cytological or histological diagnosis of pancreatic ductal adenocarcinoma or, when a tissue diagnosis is not available, imaging features typical of pancreatic ductal adenocarcinoma accepted by the multidisciplinary tumor board.
  • Resectable disease according to NCCN criteria on pancreatic-protocol contrast-enhanced CT performed within 4 weeks before surgery: no arterial tumor contact (celiac axis, superior mesenteric artery or common hepatic artery), and no contact with the superior mesenteric vein or portal vein or contact of 180 degrees or less without vein contour irregularity.
  • Planned upfront open pancreaticoduodenectomy with curative intent.
  • ECOG performance status 0 or 1.
  • American Society of Anesthesiologists (ASA) physical status I to III.
  • Written informed consent, including consent to randomization during surgery.
  • Confirmation at laparotomy, before randomization, of no peritoneal or liver metastases and no tumor involvement of the superior mesenteric artery, celiac axis or common hepatic artery.

Exclusion Criteria:

  • Borderline resectable or locally advanced disease, or distant metastases, on preoperative staging.
  • Previous chemotherapy, chemoradiotherapy or radiotherapy for the current tumor.
  • Preoperative diagnosis of another tumor type, including ampullary, distal bile duct or duodenal carcinoma, neuroendocrine neoplasm, acinar cell carcinoma, solid pseudopapillary neoplasm or lymphoma.
  • Planned total pancreatectomy or arterial resection.
  • Planned laparoscopic or robotic pancreaticoduodenectomy.
  • Previous pancreatic resection, or previous major surgery around the superior mesenteric vessels or in the retroperitoneum near the pancreas.
  • Liver cirrhosis of Child-Pugh class B or C, or portal hypertension.
  • Other active malignancy, or previous malignancy within 5 years other than non-melanoma skin cancer or carcinoma in situ of the cervix.
  • Emergency surgery for bleeding or perforation.
  • Pregnancy or breastfeeding.
  • Inability to attend follow-up or to give informed consent.
  • Participation in another interventional trial that could affect the study outcomes.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Pancreaticoduodenectomy With Total Mesopancreas Excision

Open pancreaticoduodenectomy using an artery-first approach with en bloc total mesopancreas excision: periadventitial dissection of the right hemicircumference (about 180 degrees) of the superior mesenteric artery from its aortic origin to the first jejunal artery, ligation of the inferior pancreaticoduodenal artery at its origin, and removal of the retropancreatic fat, lymphatic and neural tissue (including the right-sided superior mesenteric artery nerve plexus) down to the inferior vena cava, left renal vein and aorta, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the control arm.

Open pancreaticoduodenectomy (pylorus-preserving or pylorus-resecting) with an artery-first approach. The mesopancreas is excised en bloc with the pancreatic head and uncinate process within these boundaries: the superior mesenteric vein/portal vein axis and the right semicircumference of the superior mesenteric artery anteriorly and medially; the adventitia of the inferior vena cava, left renal vein and aorta posteriorly; the origins of the celiac trunk and superior mesenteric artery superiorly; and the lower border of the uncinate process inferiorly. The artery is cleared in the periadventitial plane over about 180 degrees on its right side from the aorta to the first jejunal artery, with ligation of the inferior pancreaticoduodenal artery at its origin; the left-sided nerve plexus is preserved. Extension up to 270 degrees is allowed only for suspected periarterial tumor extension. ISGPS standard lymphadenectomy.

Altri nomi:
  • Total mesopancreas excision (TMpE)
  • Mesopancreas excision
  • Systematic mesopancreas dissection
Comparatore attivo: Standard Pancreaticoduodenectomy

Open pancreaticoduodenectomy using the conventional vein-first approach, with division of the uncinate process from the superior mesenteric vein and the right side of the superior mesenteric artery close to the pancreas, without periadventitial dissection of the artery or resection of its nerve plexus, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the experimental arm.

Open pancreaticoduodenectomy (pylorus-preserving or pylorus-resecting) using the conventional vein-first approach: Kocher maneuver, tunneling behind the pancreatic neck and neck transection, then division of the uncinate process from the superior mesenteric vein and from the right side of the superior mesenteric artery, with ligation of the pancreaticoduodenal branches close to the pancreas. The artery is not dissected in the periadventitial plane, its nerve plexus is preserved, and the retropancreatic tissue is not excised as an en bloc compartment. ISGPS standard lymphadenectomy (stations 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a and 17b), with station 14a and 14b nodes removed superficial to the nerve plexus.

Altri nomi:
  • Procedura Whipple
  • Conventional pancreaticoduodenectomy

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
R0 Resection Rate (Tumor Clearance of 1 mm or More at All Resection Margins)
Lasso di tempo: Final histopathology report, within 3 weeks after surgery

Proportion of participants with an R0 resection on final histopathology. R0 is defined as a minimum microscopic distance of 1 mm or more between tumor and every resection margin (superior mesenteric artery margin, superior mesenteric vein/portal vein groove margin, posterior margin, pancreatic neck transection margin, bile duct margin, and proximal and distal enteric margins), assessed with a standardized protocol of multicolor inking and axial slicing. Pathologists are masked to allocation, and a second pathologist re-measures margin distances on the slides. Analyzed in randomized participants with histologically confirmed pancreatic ductal adenocarcinoma.

Final histopathology report, within 3 weeks after surgery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Superior Mesenteric Artery (Mesopancreatic) Margin Involvement
Lasso di tempo: Final histopathology report, within 3 weeks after surgery

Proportion of participants with tumor less than 1 mm from the inked superior mesenteric artery (mesopancreatic) margin on final histopathology.

Final histopathology report, within 3 weeks after surgery
R1 Direct Resection Rate (Tumor at a Resection Margin)
Lasso di tempo: Final histopathology report, within 3 weeks after surgery

Proportion of participants with tumor cells at the inked surface (0 mm) of any resection margin on final histopathology.

Final histopathology report, within 3 weeks after surgery
Number of Lymph Nodes Examined
Lasso di tempo: Final histopathology report, within 3 weeks after surgery

Total number of lymph nodes retrieved from the resection specimen and examined histologically.

Final histopathology report, within 3 weeks after surgery
Locoregional Recurrence
Lasso di tempo: From surgery up to 24 months

Cumulative incidence of locoregional recurrence (pancreatic or mesopancreatic bed around the superior mesenteric artery, celiac axis and superior mesenteric vein/portal vein, surgical anastomoses, or regional lymph nodes), isolated or combined with distant recurrence, diagnosed on contrast-enhanced CT with MRI, PET-CT or biopsy when required and adjudicated by a radiologist masked to allocation. Death without recurrence is treated as a competing event.

From surgery up to 24 months
Distant Recurrence
Lasso di tempo: From surgery up to 24 months

Cumulative incidence of recurrence in the liver, lungs, peritoneum, bone, non-regional lymph nodes or other distant sites, diagnosed and adjudicated as for locoregional recurrence. Death without recurrence is treated as a competing event.

From surgery up to 24 months
Disease-Free Survival
Lasso di tempo: From surgery up to 24 months

Time from surgery to first recurrence at any site or death from any cause, estimated by the Kaplan-Meier method and reported as the 2-year disease-free survival rate.

From surgery up to 24 months
Overall Survival
Lasso di tempo: From surgery up to 24 months

Time from surgery to death from any cause, estimated by the Kaplan-Meier method and reported as the 2-year overall survival rate.

From surgery up to 24 months
Operative Time
Lasso di tempo: During surgery

Time from skin incision to completion of skin closure, in minutes.

During surgery
Intraoperative Blood Loss
Lasso di tempo: During surgery

Estimated blood loss in milliliters, measured from suction volume and weighed swabs.

During surgery
Overall Postoperative Morbidity
Lasso di tempo: Within 90 days after surgery

Proportion of participants with at least one postoperative complication of any grade according to the Clavien-Dindo classification.

Within 90 days after surgery
Major Postoperative Morbidity (Clavien-Dindo Grade IIIa or Higher)
Lasso di tempo: Within 90 days after surgery

Proportion of participants with at least one complication of Clavien-Dindo grade IIIa or higher.

Within 90 days after surgery
Comprehensive Complication Index
Lasso di tempo: Within 90 days after surgery

Cumulative burden of all postoperative complications on a continuous scale from 0 (no complication) to 100 (death).

Within 90 days after surgery
Clinically Relevant Postoperative Pancreatic Fistula (ISGPS Grade B or C)
Lasso di tempo: Within 90 days after surgery

Proportion of participants with grade B or C postoperative pancreatic fistula according to the 2016 International Study Group of Pancreatic Surgery (ISGPS) definition.

Within 90 days after surgery
Post-Pancreatectomy Hemorrhage (ISGPS Grade B or C)
Lasso di tempo: Within 90 days after surgery

Proportion of participants with grade B or C post-pancreatectomy hemorrhage according to the ISGPS definition.

Within 90 days after surgery
Delayed Gastric Emptying (ISGPS Grade B or C)
Lasso di tempo: Within 90 days after surgery

Proportion of participants with grade B or C delayed gastric emptying according to the ISGPS definition.

Within 90 days after surgery
Chyle Leak (ISGPS Grade B or C)
Lasso di tempo: Within 90 days after surgery

Proportion of participants with grade B or C chyle leak according to the ISGPS definition.

Within 90 days after surgery
Clinically Significant Postoperative Diarrhea (CTCAE Grade 2 or Higher)
Lasso di tempo: Within 6 months after surgery

Proportion of participants with diarrhea of grade 2 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, assessed at every visit.

Within 6 months after surgery
Unplanned Reoperation
Lasso di tempo: Within 90 days after surgery

Proportion of participants who require an unplanned return to the operating room.

Within 90 days after surgery
Length of Postoperative Hospital Stay
Lasso di tempo: From surgery to discharge, up to 90 days

Number of days from surgery to hospital discharge.

From surgery to discharge, up to 90 days
Hospital Readmission
Lasso di tempo: Within 90 days after surgery

Proportion of participants readmitted to hospital after discharge.

Within 90 days after surgery
90-Day Mortality
Lasso di tempo: Within 90 days after surgery

Proportion of participants who die from any cause within 90 days after surgery.

Within 90 days after surgery
Initiation of Adjuvant Chemotherapy Within 12 Weeks
Lasso di tempo: Within 12 weeks after surgery

Proportion of participants who start adjuvant chemotherapy within 12 weeks after surgery.

Within 12 weeks after surgery
Health-Related Quality of Life (EORTC QLQ-C30 Global Health Status)
Lasso di tempo: Baseline and 3, 6 and 12 months after surgery

Global health status/quality of life score of the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire, from 0 to 100; higher scores indicate better quality of life.

Baseline and 3, 6 and 12 months after surgery

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Minimum Tumor Clearance at the Superior Mesenteric Artery Margin
Lasso di tempo: Final histopathology report, within 3 weeks after surgery

Microscopic distance, in millimeters, between the tumor and the inked superior mesenteric artery margin.

Final histopathology report, within 3 weeks after surgery
Lymph Node Ratio
Lasso di tempo: Final histopathology report, within 3 weeks after surgery

Number of metastatic lymph nodes divided by the number of lymph nodes examined.

Final histopathology report, within 3 weeks after surgery
Metastasis in Lymph Nodes Along the Superior Mesenteric Artery (Station 14)
Lasso di tempo: Final histopathology report, within 3 weeks after surgery

Proportion of participants with at least one metastatic station 14 lymph node.

Final histopathology report, within 3 weeks after surgery
Tumor Invasion of the Retropancreatic Soft Tissue or Nerve Plexus
Lasso di tempo: Final histopathology report, within 3 weeks after surgery

Proportion of participants with histological tumor invasion (direct, perineural or lymphovascular) of the resected retropancreatic soft tissue or nerve plexus.

Final histopathology report, within 3 weeks after surgery
Anterior Pancreatic Surface Involvement
Lasso di tempo: Final histopathology report, within 3 weeks after surgery

Proportion of participants with tumor at the inked anterior surface of the pancreas (0 mm).

Final histopathology report, within 3 weeks after surgery
Pattern of First Recurrence
Lasso di tempo: From surgery up to 24 months

Distribution of first recurrence as isolated locoregional, isolated distant, or combined locoregional and distant recurrence.

From surgery up to 24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Saleh Khairy Saleh, MD, Minia University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

25 novembre 2026

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

31 dicembre 2029

Date di iscrizione allo studio

Primo inviato

13 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 1702-09-2025

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .